Endocrine Abstracts

Contents

• 15th Annual Meeting of the UK and Ireland Neuroendocrine Tumour Society 2017
• • Speaker Abstracts
  • • The role of biomarkers in the management of neuroendocrine tumours

      ea0052nets1
    • The role of pathology and the new WHO classification

      ea0052nets2
    • Abstract unavailable

      ea0052nets3
    • Role of Multimodality Imaging

      ea0052nets4
    • Neo-adjuvant and adjuvant treatment in bronchial NETs

      ea0052nets5
    • Type I gastric NETs: Surveillance, Endoscopic Resection or Surgery

      ea0052nets6
    • Refractory hypoglycaemia in advanced insulinomas

      ea0052nets7
    • Abstract unavailable

      ea0052nets8
    • Abstract unavailable

      ea0052nets9
    • Abstract unavailable

      ea0052nets10
    • Debate: There is a role in resection of NET hepatic metastases - surgical dilemma

      ea0052nets11
    • Abstract unavailable

      ea0052nets12
    • Abstract unavailable

      ea0052nets13
    • Abstract unavailable

      ea0052nets14
    • The evolving landscape in Nuclear Medicine in NETs

      ea0052nets15
    • Abstract unavailable

      ea0052nets16
• Oral Communications
• • (1)
  • • A predictive quotient index, comprising neuroendocrine gene cluster analysis in blood and tissue grading is specifically predicts PRRT efficacy

      ea0052oc1
    • Systematic evaluation of the immune microenvironment of neuroendocrine tumours

      ea0052oc2
    • Incidence and prevalence of neuroendocrine tumours in England

      ea0052oc3
• Poster Presentations
• • (1)
  • • Genetics and diagnostic characterisation of bladder paragangliomas

      ea0052p01
    • Validation of a blood biomarker test for the diagnosis and management of bronchopulmonary neuroendocrine tumors

      ea0052p02
    • Blood measurements of Neuroendocrine Tumor (NET) transcripts and gene cluster analysis predict efficacy of PRRT

      ea0052p03
    • A liquid biopsy for the diagnosis and monitoring of bronchopulmonary/lung carcinoid

      ea0052p04
    • Incidence of PCC/PGL in mutation positive family members at first contact

      ea0052p05
    • Nutritional assessment and vitamin deficiencies in patients with NETs

      ea0052p06
    • Piloting a group programme aiming at psychologically supporting neuroendocrine patients

      ea0052p07
    • Audit of a new nurse-led non-medical prescribing (NMP) clinic for systemic anti-cancer agents (SACTs)

      ea0052p08
    • Audit of South Wales Neuroendocrine MDT pathology reports

      ea0052p09
    • Neuroendocrine Tumour (NET) patients experiences of support in the community setting across the cancer treatment trajectory

      ea0052p10
    • The Missing Malignancies - Follow up of patients with pulmonary carcinoid tumours in the UK: Results from the National Lung NET Pathway ('LEAP') project

      ea0052p11
    • 1-Year survival rates for neuroendocrine tumour patients in England

      ea0052p12
    • Metachronous primary cancers in neuroendocrine tumour patients

      ea0052p13
    • Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period

      ea0052p14
    • Platinum-etoposide chemotherapy for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC): A survey of clinical practice

      ea0052p15
    • Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: post-hoc analyses from TELESTAR

      ea0052p16
    • Surgical therapy for appendiceal neuroendocrine tumours: is appendicectomy adequate?

      ea0052p17
    • Circulating Tumour Cells (CTCs) are associated with bone metastases in patients with Neuroendocrine Tumours (NET)

      ea0052p18
    • Mixed Adeno-Neuroendocrine Carcinoma (MANEC): a multicentre retrospective study

      ea0052p19
    • Prophylactic right hemicolectomy in Appendiceal Neuroendocrine Neoplasms: challenging the current indications

      ea0052p20
    • Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence

      ea0052p21
    • Above-label doses of lanreotide Autogel for the treatment of advanced neuroendocrine tumours (NETs)

      ea0052p23
    • Shortened interval of octreotide LAR administration for the treatment of advanced neuroendocrine tumours (NETs)

      ea0052p24
    • Multi-parametric assessment improves prognostication of small bowel neuroendocrine neoplasms: external validation of the NET nomogram

      ea0052p26
    • Supplementation of vitamin D deficiency/insufficiency in patients with GEP-NET using over the counter vitamin D3 preparations

      ea0052p27
    • Outcomes of radical treatment of NET Liver Metastases: a single tertiary centre 18-year experience

      ea0052p28
    • Endoscopic submucosal dissection (ESD) of gastric and rectal neuroendocrine tumours (NETs)

      ea0052p29
    • Outcomes of surgical and endoscopic resection of duodenal NETs: a systematic review of the literature

      ea0052p30
    • The utility of the KI67-Index in predicting pulmonary carcinoid metastasis: a single centre experience

      ea0052p31
    • Impact of somatostatin analogues on quality of life in patients with neuroendocrine tumours

      ea0052p32
    • Double-balloon enteroscopy (DBE) is useful and effective for the diagnosis, assessment and management of small bowel neuroendocrine tumours (SBNETs): a case series from a national tertiary referral centre

      ea0052p33
    • Grading systems in gastroenteropancreatic neuroendocrine tumours

      ea0052p34
    • A family of SDHB mutation and paraganglioma Alam K, Owen D, Ganatra R, Nakas A, Lloyd D, Levy MJ university hospitals of Leicester NHS trust

      ea0052p35
    • Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

      ea0052p36
    • Choroidal metastases as a Harbinger of Metastatic Typical Pulmonary Carcinoid: regression and stability with Lanreotide autogel

      ea0052p37
    • Paraneoplastic syndrome or De Novo diagnosis?: Metastatic small bowel neuroendocrine tumour presenting with Giant cell arteritis

      ea0052p38
    • A case of carcinoid crisis despite high dose somatostatin analogue therapy peri-operatively

      ea0052p39
    • Pancreatic VIPoma - a diagnostic and symptom control challenge

      ea0052p40
    • Two cases of metastatic neuroendocrine tumours stabilised with somatostatin analogues

      ea0052p41
    • Therapeutic options in metastatic phaeochromocytomas

      ea0052p42